Osteonecrosis of the jaw among patients with cancer treated with denosumab or zoledronic acid: Results of a regulator‐mandated cohort postauthorization safety study in Denmark, Norway, and Sweden

BACKGROUND Osteonecrosis of the jaw (ONJ) is an adverse effect of antiresorptive treatment. This study estimated incidence proportions and incidence rates of ONJ in cancer patients with bone metastases from solid tumors treated for the prevention of skeletal‐related events in routine clinical practi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer 2021-11, Vol.127 (21), p.4050-4058
Hauptverfasser:	Ehrenstein, Vera, Heide‐Jørgensen, Uffe, Schiødt, Morten, Akre, Olof, Herlofson, Bente Brokstad, Hansen, Svein, Larsson Wexell, Cecilia, Nørholt, Sven Erik, Tretli, Steinar, Kjellman, Anders, Glennane, Anthony, Lowe, Kimberly A., Sørensen, Henrik T.
Format:	Artikel
Sprache:	eng
Schlagworte:	Acids Adjudication american association Biomedical materials Bisphosphonate-Associated Osteonecrosis of the Jaw - drug therapy Bisphosphonate-Associated Osteonecrosis of the Jaw - epidemiology Bisphosphonate-Associated Osteonecrosis of the Jaw - etiology bisphosphonates Bone cancer Bone Density Conservation Agents - adverse effects Bone Neoplasms - secondary Bone surgery Bone tumors breast Breast cancer Cancer Cancer and Oncology Cancer och onkologi Clinical medicine Cohort analysis Cohort Studies cohort study Confidence intervals Denmark - epidemiology denosumab Denosumab - adverse effects Diphosphonates - adverse effects Fractures Humans Jaw Male Metastases Monoclonal antibodies Oncology Osteonecrosis osteonecrosis of the jaw Pain Patients prevention Prostate Prostate cancer real-world data routinely collected health data Solid tumors surgeons position paper Sweden Tumors Zoledronic acid Zoledronic Acid - adverse effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!